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1. BACKGROUND AND SIGNIFICANCE 
 
Runx2/Cbfa1 is a bone-related transcription factor homologous to the Drosophila 
protein, Runt (Ducy, 2000). Runx2 protein is essential for the differentiation of 
osteoblasts from mesenchymal precursors, and bone formation, as homozygous Cbfa1-/- 
mice show a complete lack of functional osteoblasts and are devoid of mineralized bone 
or hypertrophic cartilage (Otto et al., 1997). Mutations in Runx2 on the short arm of 
Chromosome 6 in humans cause cleidocranial dysplasia (CCD), an autosomal dominant 
disease characterized by the absence of clavicles, open fontanelles, supernumerary teeth 
and short stature (Mundlos et al., 1997); (Bergwitz et al., 2001).  Runx2 can directly 
stimulate transcription of osteoblast-related genes such as those encoding osteocalcin 
(OCN), bone sialoprotein (BSP), type I collagen, osteopontin (OPN) and collagenase 3 
by binding to specific enhancer regions containing the core sequence, PuCCPuCA (Ducy 
et al., 1997). 
Runx2/Cbfa1 is present in tooth germs (odontoblasts, ameloblasts, 
cementoblasts), and some stages of cartilage and osteoblasts (Wise et al., 2002; 
Yamashiro et al., 2002; Pan et al., 2005).  It is essential for differentiation of 
mesenchymal cells into bone-specific cell types or tooth and mineralization in vivo (Chen 
et al., 2005b). Runx2 gene knockout mice are unable to mineralize their skeletons and 
exhibit an arrest of tooth development at the cap stage (Aberg et al., 2004a). Thus, Runx2 
plays fundamental roles in the development of bones and teeth.  
The transition from preosteoblasts to osteoblasts involves the secretion of a 
complex extracellular matrix (ECM) containing bone morphogenic proteins (BMP), 
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growth factors and structural components that interact with cells to induce osteoblast-
specific gene expression (Xiao et al., 2002c). The mitogen-activated protein kinase 
(MAPK) pathway is critical for the responsiveness of osteoblasts to ECM, hormonal, 
growth factor and mechanical stimili (Xiao et al., 2002a; Xiao et al., 2002c; Franceschi et 
al., 2003; Jiang et al., 2004). Differentiation is controlled in part by binding of type I 
collagen to 2 1 integrins that signal to the nucleus via the ERK/MAPK pathway to 
phosphorylate and activate the osteoblast-related transcription factor, RUNX2 (Xiao et 
al., 1998a). Other growth factors such as FGF2 and IGF, known to signal through 
MAPK, also stimulate RUNX2 phosphorylation (Xiao et al., 2002c). The significance of 
MAPK signaling in osteoblast differentiation was established by showing that 
perturbation of this pathway through the use of specific inhibitors or expression of 
constitutively active or dominant negative MAPK intermediates, respectively, increased 
or decreased osteoblast differentiation in cell culture and in transgenic mice. My proposal 
will focus on identifying and characterizing domains in Runx2 that are phosphorylated by 
MAPK and necessary for transcriptional activation. The functional activity of specific 
domains will be established by mutagenesis and testing in bone cells from Runx2-
deficient mice. Phosphorylation of Runx2 will also be examined. In this way, we will be 
able to show how a specific modification of the Runx2 transcription factor can alter its 
transcriptional activity. This pathway may also be active in odontoblasts since this cell 
type is also known to be dependent on ECM synthesis for differentiation. 
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The phosphorylation sites identified in this study will serve as the basis for future 
work to assess the importance of Runx2 phosphorylation in vivo.  This will be 
accomplished through the development of a knock-in model in which inactive mutations 
will be introduced into the endogenous Runx2 gene. These animals can be used to assess 
the role of Runx2 phosphorylation in bone formation and remodeling, mechanical loading 
of bone, and tooth development and movement.  
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2. PURPOSE AND HYPOTHESES 
 
2.1 PURPOSE  
The purpose of this research is to establish the importance of MAPK 
phosphorylation sites to the biological activity of RUNX2 in cell culture by identifying 
and characterizing MAPK phosphorylation sites in RUNX2.  
 
2.2 HYPOTHESES 
MAPK phosphorylation sites in RUNX2 are critical for responsiveness to several 
extracellular matrix (ECM) and hormonal signals, and are necessary for Runx2-
dependent gene expression. 
 
2.3 SPECIFIC AIM 
Identify and establish the importance of MAPK phosphorylation sites to the 
biological activity of RUNX2. Studies in this aim will identify domains of Runx2 
necessary for MAPK responsiveness and evaluate the role of MAPK phosphorylation 
sites in the response of osteoblasts to a known osteoblast-related inducer of MAPK 
activity, FGF2, in cell culture. Studies with FGF2 will use a reconstituted system in 
COS7 cells (Runx2-negative) containing an OCN promoter-Luc reporter and Runx2 
deletions/mutations and measure FGF2-induced luciferase activity.  
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3. REVIEW OF LITERATURE 
The runt box (Runx) is a highly conserved DNA binding and protein-protein 
interaction domain that defines a family of heterodimeric transcription factors with 
essential roles in multicellular animal development.  
3.1 Runx family  
The first member of Runx family to be identified was the Drosophila regulatory 
gene runt, which was named by virtue of its function in establishing segmentation 
patterns during embryogenesis, and subsequently discovered to have additional functions 
in sex determination and neurogenesis. A second Drosophila Runx gene, lozenge, is 
required for cell patterning in the eye and for hematopoiesis. The genome project has 
revealed the existence of two additional Drosophila Runx genes, which have not been 
fully characterized. Other invertebrate species with well-characterized Runx transcription 
factors include the nematode, Caenorhabditis elegans, and the sea urchin, 
Strongylocentrotus purpuratus, each of which apparently contains only a single Runx 
gene (Coffman, 2003).  
The Runx family of transcription factors has a variety of functions in normal 
development and neoplasia. In mammals, the Runx gene family consists of 
RUNX1/AML1, RUNX2 and RUNX3(van Wijnen et al., 2004). Runx1 is required for 
hematopoiesis and is genetically altered in leukemia. Indeed, it is the most frequent target 
of chromosomal translocations associated with human leukemias (Look, 1997; Speck and 
Gilliland, 2002). Moreover, haploinsufficiency of RUNX1 due to heterozygous loss-of-
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function mutations is associated with familial platelet disorder with a predisposition to 
acute myeloid leukemia (FPD-AML) (Song et al., 1999). Sporadic heterozygous 
mutations of RUNX1 are also leukemogenic (Osato et al., 1999). In addition, RUNX1 is 
associated with several autoimmune diseases, such as systemic lupus erythematosus, 
rheumatoid arthritis and psoriasis (Prokunina et al., 2002; Tokuhiro et al., 2003). 
Runx2, also known as Core-binding factor α1 (Cbfa1), PEBP2A1, AML3, is a 
bone-related runt domain transcription factor (Ducy, 2000). The Runx2 gene encodes a 
master transcription factor of bone and plays a role in all stages of bone formation 
(Karsenty, 2001; Lian and Stein, 2003). It also plays an important role in the 
development of dentition (D'Souza et al., 1999; Gaikwad et al., 2001; Wise et al., 2002; 
Aberg et al., 2004a; Aberg et al., 2004b; James et al., 2006; Ryoo and Wang, 2006).  
RUNX3 is required for the development of CD8-lineage T cells (Taniuchi et al., 
2002) and TrkC-dependent dorsal root ganglion neurons (Inoue et al., 2002). It also 
functions as a tumor suppressor (Bae and Choi, 2004). It is associated not only with 
gastric cancer, but also with various other cancers of the lung, colon, pancreas, liver, 
prostate, bile duct, breast, larynx, esophagus, endometrium, uterine cervix and testicular 
yolk sac (Bae and Lee, 2006). 
During development, Runx1, Runx2, and Runx3 are all expressed in 
mesenchymal condensates. Runx1 is expressed in several cartilage primordia earlier than 
Runx3, and Runx2 is intensely expressed in all mesenchymal condensations of bones and 
teeth. Only Runx1 is expressed in epithelia, and in tooth germs transcripts where it was 
detected in outer dental epithelium and midline epithelium of palatal shelves. In early 
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tooth morphogenesis, Runx3 is coexpressed with Runx2 in a thin layer of mesenchymal 
cells underlying dental epithelium. Runx3 is expressed in odontoblasts. However, Runx3 
mutant mice do not show an obvious tooth phenotype or deviations of Runx1 and Runx2 
expression patterns in the tooth (Yamashiro et al., 2002). 
3.2 Runx2 and bone 
Bone tissue consists of hydroxyapatite crystals and various kinds of extracellular 
matrix (ECM) proteins, including type I collagen, osteocalcin (OCN), bone sialoprotein 
(BSP), osteonectin, osteopontin (OPN), and proteoglycans (Young et al., 1992). These 
bone matrix proteins are secreted and deposited by polarized mature osteoblasts, which 
are aligned on the bone surface. The precise roles of matrix proteins in the formation of 
bone have not been fully elucidated. The formation of hydroxyapatite crystals is also 
regulated by osteoblasts (Horowitz, 2003; Young, 2003). The Runx2 gene is 220kb long 
(Levanon et al., 1994; Yamashiro et al., 2002) and contains eight exons (Geoffroy et al., 
1998; Xiao et al., 1998b; Quack et al., 1999). Runx2 is essential for osteoblast 
development and proper bone formation. Runx2 binds specific DNA sequences to 
regulate transcription of numerous genes and thereby control osteoblast development. 
Runx2 is essential for the initial commitment of mesenchymal cells to the osteoblastic 
lineage, and also controls the proliferation, differentiation, and maintenance of these 
cells. Runx2 expression persists throughout bone development beginning at embryonic 
day 9.5 (E9.5) in mouse where it peaks at E12.5, well before any mineralization has 
occurred. After very early expression of Runx2 in skeletal development, it continues 
during the later stages of bone development and persists in regions of active bone 
remodeling throughout life (Karsenty, 2001).  Although necessary for gene transcription 
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and skeletal development, Runx2 is not sufficient for optimal gene expression or bone 
formation. The subsequent development of the osteoblast linage requires cooperation 
between Runx2 and several other proteins, including transcription factors and cofactors 
such as Ostrix, which is essential for subsequent progression of the osteoblast linage, and 
ATF4, which regulates osteoblast activity, particularly in postnatal animals (Nakashima 
et al., 2002; Yang et al., 2004). Runx2 is posttranslationally modified, and associates with 
the nuclear matrix to integrate a variety of signals and organize crucial events during 
osteoblast development and maturation. Consistent with its role as a master organizer, 
alterations in Runx2 expression levels are associated with skeletal diseases (Schroeder et 
al., 2005).  
  In vivo studies of homozygous Runx2-/- mice show no bone tissue, osteoblasts or 
osteoclasts, despite normal cartilaginous skeletal patterning. However, chondrocyte 
maturation to the hypertrophic stage is also blocked (Komori et al., 1997; Otto et al., 
1997). Mice lacking Runx2 show a complete absence of osteoblasts and bone and 
succumb at birth due to respiratory distress caused by a defective rib cage (Ducy et al., 
1997).  
Runx2 overexpression is common in many bone-metastatic cancers (Pratap et al., 
2005; Schroeder et al., 2005), and adult transgenic mice overexpressing Runx2 showed 
osteopenia with a decrease in bone mineral density (Geoffroy et al., 2002). Also, over 
expression of Runx2 in lymphocytes induces T-cell Leukemia ((Vaillant et al., 2002)). 
In vitro studies showed that growth factors with known osteoinductive abilities, 
like the BMPs, regulate Runx2 expression in osteoblasts (Ducy et al., 1997; Xiao et al., 
2002a). Runx2 also binds to and regulates the expression of multiple extracellular matrix 
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genes in osteoblasts, and its overexpression can induce osteoblast-specific gene 
expression in fibroblasts and myoblasts (Ducy et al., 1997). These results firmly establish 
the role of Runx2 as a key transcriptional regulator of osteoblast differentiation during 
bone formation. In vivo and in vitro studies indicate that Runx2 is a master gene of 
osteoblast differentiation whose function is not redundant with that of other genes in vivo.  
 
3.2.1 Runx2 structure and function 
RUNX2 binds to the osteoblast-specific cis-acting element 2 (OSE2), the core 
binding factor site, (Ducy and Karsenty, 1995), which is found in the promoter regions of 
all the major osteoblast-characteristic genes, such as osteocalcin, type I collagen, BSP, 
osteopontin, MMP-13, and alkaline phosphatase (ALK). Together with other factors, it 
controls their expression. The runt homology domain (RHD) is responsible for the DNA-
binding of Runx2. Three transactivation domains and one major repression domain have 
been identified in the RUNX2 protein (Fig.1). The first transactivation domain is located 
in the N-terminal 19 amino acids of the protein, while the second is located in the 
glutamine/alanine (Q/A) domain. The transactivation depends on glutamine residues. 
Deletion of the alanine does not affect transactivation; however, expansion has a 
repressive function, and expansion may also play a role in nuclear localization (Albrecht 
et al., 2004). The third activation domain is present in the N-terminal portion of the 
proline/serine/threonine (PST)-rich domain. A mutation in this region blocked 
interactions with SMADs, reducing the response of osteoblasts to the Transforming 
growth factor-β/Bone morphogenetic protein (TGF-β/BMP) signaling pathway (Zhang et 
al., 2000).  
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The C-terminal part of the PST domain is a repression domain (Thirunavukkarasu 
et al., 1998). Studies identified several co-repressor proteins that bind to Runx2 to 
regulate gene expression, such as histone deacetylases (HDACs), transducin-like 
enhancer of split (TLE) proteins, mSin3a, and yes-associated protein (YAP). These 
proteins do not bind DNA themselves and appear to act by preventing Runx2 from 
binding DNA, altering chromatin structure, and/or by possibly blocking co-activator 
complexes. The nuclear localization of several of these factors is regulated by 
extracellular signaling events (Westendorf, 2006). 
RUNX2 is imported to the nucleus after transcription and must bind to specific 
regions of the nuclear matrix to effect transcriptional control, colocalizing with co-
activators such as SMADs and RNA polymerases, at nuclear sites that support RNA 
synthesis. This function is affected by the nuclear matrix targeting signal (NMTS) region, 
which is a 38 amino acid segment situated between the RHD and PST domains. Point 
mutations in the NMTS region have been shown to affect the intranuclear localization of 
RUNX2, possibly affecting its interaction with target genes that are involved in 
osteogenic activity (Zhang et al., 2000). The interaction of transcription factors with 
cellular signal transducers at particular points in the nuclear matrix may partly explain the 





Fig. 1. Runx2 structure. The Runx2 proteins contain multiple functional domains: 
AD1-3, transactivation domains; QA, glutamine/alanine rich domain; RUNT, runt 
homology domain; NLS, nuclear localization signal; PST, 
proline/serine/threonine rich domain; NMTS, nuclear matrix targeting signal; 
RD, repression domain; VWRPY, conserved repression “domain” of runt 
proteins. HDAC, histone deacetylase; mSin3A, SIN3A protein; TLE, transducin-
like enhancer of split; YAP, yes-associated protein.     
     (Edit from Ziros et al., 2008) 
 
3.2.2 Runx2 isoforms and expression 
Runx2 has two major N-terminal isoforms that are separately transcribed from a 
proximal promoter or a distal promoter (Fig.2). The P2 promoter drives expression of the 
Type I isoform, which is associated with cell proliferation. The P1 promoter drives 
expression of the type II isoform, which appears to be the bone-specific Runx2 isoform. 
The product of the proximal promoter starts with a different amino acid sequence (Xiao 
et al., 1998b). The presence of multiple isoforms of Runx2 gene product is similar to the 





Fig 2. Runx2 isoforms. The runx2 gene contains eight exons and its transcription 
is controlled by two promoters, P1 and P2, which give rise to two major 
transcripts/protein isoforms, type II and type I, respectively. Runx2-Type I, 
associates with cell proliferation; Runx2-Type II, commitment to a calcified tissue 
line.    
        (Edit from Ziros et al., 2008) 
 
Runx2 can directly stimulate transcription of osteoblast-related genes such as 
those encoding osteocalcin (OCN), type I collagen, bone sialoprotein (BSP), osteopontin 
(OPN) and collagenase 3 by binding to specific enhancer regions containing the core 
sequence, PuCCPuCA (Ducy et al., 1997). Over expression of a dominant-negative 
Runx2 fragment was shown to suppress bone formation in post natal animals thereby 
proving its role in bone remodeling as well as formation (Ducy et al., 1999). 
RUNX2 is essential for normal bone formation, with perturbation of bone 
formation if the levels are insufficient. Overproduction also affects bone formation. 
Osteoblasts taken from non-syndromic synostosed sutures in children exhibited an 
increase in Runx2 expression, possibly explaining the enhanced proliferation and bone-
forming ability of these cells (Shevde et al., 2001). However, osteopenia with a decrease 
in bone mineral density were observed in adult transgenic mice which overexpress 
Runx2. This was attributed to reduce osteoblast maturation, and also to enhanced receptor 
activator of nuclear factor kappa β ligand (RANKL) and matrix metalloproteinase-13 
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(MMP-13) production with enhanced osteoclastogenesis (Geoffroy et al., 2002). 
Maturational blockage of osteoblasts was observed in neonatal transgenic mice, but no 
enhanced osteoclastogenesis shown (Liu et al., 2001). Runx2 is regulated partially 
through a negative feedback loop by activity of the RUNX2 protein on its own promoter, 
to control variations in gene expression and function during osteogenesis (Drissi et al., 
2000). Runx2 expression decreases with age, which may be one possible explanation for 
impaired osteoblast function and reduced bone formation with aging (Christiansen et al., 
2000). 
RUNX2 is regulated by a variety of signaling pathways. Binding of ECM proteins 
to cell-surface integrins, mechanical loading, fibroblast growth factor 2 (FGF2), 
parathyroid hormone (PTH), and bone morphogenetic proteins (BMP), all influence 
RUNX2-dependent transcriptional activity. In many cases, Runx2 activity rather than 
protein levels are regulated via post transcriptional modification by the mitogen-activated 
protein kinase (MAPK) and protein kinase A and C (PKA, PKC) pathways. These 
pathways alter the phosphorylation state of Runx2. (Xiao et al., 1997; Xiao et al., 1998a; 
Xiao et al., 2000; Xiao et al., 2002a; Xiao et al., 2002c; Jiang et al., 2004). Further 
control of the RUNX2 molecule occurs through the counterplay of acetylation and 
ubiquitinization (Bae and Lee, 2006). The Runx2 gene, in fact, plays a central role in co-
coordinating multiple signaling pathways affecting osteoblast differentiation. 
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3.2.3 Bone and Osteocalcin (OCN) 
The osteocalcin (OCN), an osteoblast-derived hormone (Karsenty, 2008) used as a 
specific bone marker, is an excellent tool since it is expressed in vivo in osteoblasts and 
their tooth counterparts, the odontoblasts, and in no other extracellular matrix-producing 
cells. In mouse, there are two osteocalcin-encoding genes expressed in osteoblasts and 
odontoblasts only, mOG1 and mOG2 (Desbois et al., 1994). They encode the same 
protein and display the same expression pattern, and their proximal promoter regions are 
93% identical over the first 1.3 kb (Desbois et al., 1994). To understand the mechanisms 
leading to cell-specific OCN gene expression, studies were conducted on the promoter 
element of this gene in different laboratories. The results showed that a 200-bp fragment 
of the rat promoter and a 160-bp fragment of the mouse OG2 promoter were necessary 
and sufficient to confer osteoblast-specific expression to a reporter gene. Two osteoblast-
specific cis-acting elements were characterized in this mOG2 promoter fragment (termed 
OSE1 and OSE2) that were able to confer osteoblast-specific activity to a heterologous 
promoter (Frendo et al., 1998), while OSE2 is the binding site for Runx2 (Ducy et al., 
1997).  
 
3.3 Runx2 and Tooth 
Runx2 expression has been reported in pre-osteogenic mesenchyme and active 
osteogenesis sites, as well as in developing tooth organs in the mouse (Ducy et al., 1997; 
Komori et al., 1997; Otto et al., 1997; D'Souza et al., 1999). 
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In mammalian tooth development, the cranial neural crest-derived dental 
mesenchyme consists of the dental papilla and dental sac, which give rise to dental pulp 
and odontoblasts, as well as the periodontium, including the osteoblasts that contribute to 
the alveolar process. The alveolar process is a specialized intramembranously formed 
bone, which provides the primary support structure for the dentition. 
In both the dental papilla and dental sac, Runx2 expression suggests a potential 
involvement of this gene in the differentiation of odontoblasts and osteoblasts lining bone 
in the periodontal space. RUNX2 deficient mice exhibit an arrest of molar tooth 
development at the early bud/cap stage, which suggests a requirement for RUNX2 in the 
progression of tooth development from the cap stage to the bell stage (D'Souza et al., 
1999).  
Runx2 /  mouse molars show arrested development at the bud/cap stage. 
However, the incisors, which develop earlier, progress to the bell stage and show dentine 
formation, although odontoblasts are abnormal and no enamel is formed (D'Souza et al., 
1999; Aberg et al., 2004a; Aberg et al., 2004b). Enamel knot marker genes, such as 
cyclin-dependent kinase inhibitor 1A (p21), Fgf4, ectodysplasin A receptor (Edar) and 
Bmp4, are down-regulated in Runx2 /  lower molars, while expressed normally in the 
upper molars. Sonic Hedgehog (Shh) is completely absent in Runx2 /  lower molars, 
while weak signals remain at the tip of the tooth bud in the upper molars (Aberg et al., 
2004b). Lower molars are more severely affected than upper molars in Runx2 /  mice, 
and incisors are less affected than molars. Therefore, RUNX2 may have different 
downstream target genes in different regions of the jaw. The different origins of the 
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neural crest cells give rise to maxillary and mandibular structures with different 
characteristics and origin. Although both odontoblasts and osteoblasts are derived from 
mesenchyme, their developmental profiles of Runx2 expression are different, suggesting 
that the gene may also be differentially regulated in these cells (D'Souza et al., 1999). 
Before crown development, Runx2 is strongly expressed in dental papilla 
mesenchyme, which gives rise to the pulpal cells and odontoblasts. Runx2 is markedly 
down-regulated at the bell stage in the dental papilla after morphogenesis is complete. 
The expression continues, although at a lower level, in the cells of the dental papilla, 
particularly near the apical portion, as well as in the odontoblasts lining the pulp 
chamber. Expression is evident throughout the further development of the tooth and at all 
stages of root formation, including formation of the periodontium. Cementoblasts, 
cementocytes, periosteal tissue, osteoblasts, and osteocytes all showed expression of 
Runx2. No Runx2 expression was found in osteoclasts. The forming periodontium 
contains a decreasing gradient of transcripts and Runx2 immunostaining from crown to 
the root tip (Bronckers et al., 2001). 
Runx2 expression is initiated by fibroblast growth factor (FGF) produced by the 
odontogenic epithelium in mouse embryonic mandibular first molar tooth germs, shortly 
after epithelial thickening, and is followed by expression of RANKL in the early alveolar 
bone ossification centers and that of its receptor, receptor activator of nuclear factor 
kappa B (RANK) and OPG in tooth bud epithelium and mesenchyme. Thus, Runx2 is not 
involved in the initiation of tooth formation, but is intimately involved in regulating the 
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expression of mesenchymal molecules that act reciprocally on the epithelium to control 
the differentiation of the enamel organ (D'Souza et al., 1999; Aberg et al., 2004b). 
Runx2 is thus essential for tooth development up to the bell stage, being necessary 
for the formation of the enamel knot, which controls growth and folding of the enamel 
organ epithelium. Runx2 is a mesenchymally expressed gene that regulates epithelial 
morphogenesis. It plays an important role in the differentiation of mineralized tooth 
matrix-producing cells, and its expression in dental mesenchyme is stimulated by 
epithelial-mesenchymal interactions and by FGFs. Whether Runx2 is essential for the 
later stages of tooth development is still unknown, as Runx2 /  mice do not survive 
beyond birth. 
3.3.1 Runx2 and Ameloblasts 
 The development of the tooth germ requires complicated molecular interactions that 
are influenced by the expression of various genes. The expression of Runx2 is related to 
the development and differentiation of the tooth germ and controls downstream factors 
acting on the development of the enamel organ epithelium. Pre-ameloblasts show no 
Runx2 mRNA expression, however, it is strongly up-regulated in maturational phase 
cells. RUNX2 is present in late secretion stage and maturation stage of ameloblasts. The 
importance of Runx2 in amelogenesis is evidenced by the lack of enamel in the incisor 
tooth germs of Runx2 /  mice. (D'Souza et al., 1999).  
 Ameloblastin (AMBN), an extracellular matrix protein, may play a role in enamel 
crystal formation during tooth development. AMBN is used as an ameloblast-specific 
gene marker. Interestingly, there are two Runx2-binding sites in the murine Ambn 
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promoter. Runx2 can interact with the Ambn promoter at these functionally important 
regions, and mutation of the Runx2-binding sites in Ambn promoter resulted in 
diminishing promoter activity. This indicates that Runx2 has an important function in 
transcription of the Ambn gene. The type II isoform of Runx2 mRNA remains strongly 
expressed in both immature and mature ameloblast, suggesting that Runx2 is involved in 
the early stages of enamel organ formation, and tooth morphogenesis. It may also play a 
direct role in formation of tooth enamel (D'Souza et al., 1999). Histologically, the study 
of extracted permanent teeth in CCD show evidence of hypoplasia (Fukuta et al., 2001). 
3.3.2 Runx2 and Odontoblasts 
Odontoblasts and Osteoblasts share several similarities, such as the expression of 
similar genes. The main non-collagenous components of the odontoblastic extracellular 
matrix dentin sialophosphoprotein or dentin matrix protein 1 (DSPP or DMP1) are also 
present in other tissues, such as osteoblasts and periodontium, although at much lower 
levels. The regulation of Dspp gene expression is dependent on the state of differentiation 
of the target cell (Chen et al., 2005a).  
RUNX2 is also involved in the regulation of DMP1 in osteoblasts, although it is 
not essential for DMP1 expression in odontoblasts, which indicates the involvement of 
other unidentified odontoblast-specific transcription factors or co-activators (Narayanan 
et al., 2001).  
Proliferation and differentiation in Runx2+/  human primary pulp cells are 
different to wild-type cells as a result of variations in gene expression patterns and 
signaling. Thus, haploinsufficency may well influence the differentiation of odontoblasts 
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from these cells. Runx2 is up-regulated in early odontoblasts, showing that levels of 
RUNX2 are necessary at this stage. However, unlike in osteoblasts, Runx2 expression is 
significantly reduced or undetectable in differentiated odontoblasts (Bronckers et al., 
2001). This down-regulation of expression in newly differentiated and functional 
odontoblasts suggests that Runx2 plays an essential and stage-specific role in the lineage 
determination and terminal differentiation of odontoblasts from dental papilla 
mesenchyme. It also elucidates the different effects of this gene in different tissues. 
3.3.3 Runx2 and Cementoblasts 
Cementoblasts share many characteristics with osteoblasts. It is unclear whether 
osteoblasts and cementoblasts arise from a common precursor cell (Bosshardt, 2005). 
Cementoblasts express Runx2 mRNA and protein at different levels. Recently, 
immunolocalization patterns of Runx2 were examined during rat molar tooth formation. 
Colocalization of Runx2 was detected in cementoblasts, which penetrated the ruptured 
Hertwig's epithelial root sheath and attached to root dentin. Moreover, osteopontin was 
observed in Runx2-positive cementoblasts facing the root surface. However, the cells 
adjacent to cementoblasts showed only Runx2 reactivity. No Runx2 was seen in 
cementocytes. These results suggest that Runx2 is important for differentiation into 
cementoblasts (Hirata et al., 2009).  
Variations in cementum formation have been observed in CCD. Both acellular 
and cellular cementum formation is defective in permanent teeth in CCD, but not in 
deciduous teeth. Runx2+/- showed inconsistent result as well (Camilleri and McDonald, 
2006). 
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3.3.4 Runx2 and Periodontal Ligament 
Runx2 is also expressed in periodontal ligament (PDL) fibroblasts, although BSP, 
a marker of osteoblast differentiation is not and biomineralization is not seen. Periodontal 
ligament cells and osteoblasts located on the alveolar bone surface showed 
immunoreactivity for Runx2 (Hirata et al., 2009). RUNX2 is suppressed by a mechanism 
designed to maintain PDL width by S100A4, a member of the S100 calcium-binding 
protein family. S100A4 is synthesized and secreted by PDL cells, and may act as an 
inhibitor of mineralization (Kato et al., 2005). However, the PDL cells retained the 
potential to differentiate to osteoblasts under certain conditions, such as mechanical 
stress. Deformation of PDL osteoblasts increases Runx2 expression, protein levels, and 
also its DNA-binding activity. These changes may be initiated by deformation-dependent 
activation of the ERK (extracellular signal related kinase) MAPK pathway. However, the 
PDL response to stress did not show difference between heterozygous and wild-type mice 
(Ziros et al., 2002). 
 
3.3.5 Runx2 and Tooth Maturation and Eruption 
Dental follicle is a loose connective tissue sac that surrounds the unerupted tooth. 
It differentiates into the periodontal ligament, and may be the precursor of other cells of 
periodontium, including osteoblasts and cementoblasts, and plays different roles at 
different times in the life of a tooth (Yao et al., 2008). It initiates eruption by regulating 
alveolar bone resorption and formation. Dental follicle is required for eruption (Cahill 
and Marks, 1980; Marks and Cahill, 1984). During alveolar and root growth, the 
microenvironment is altered within the superior aspects of the crypt. Consequently, the 
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activation of transcription factors, cytokines, and growth factors leads to the recruitment 
and activation of osteoclasts by the dental follicle. The presence of osteoblasts is required 
for the activation of osteoclasts via the RANKL/OPG pathway. Evidence supports a role 
for Runx2 in molecular events that regulate tooth eruption (Wise et al., 2002). 
Different teeth appear to be regulated by different molecules and mechanisms. 
Epidermal growth factor (EGF) accelerates rodent incisor eruption, but has little effect on 
the molar (Lin et al., 1992), whereas colony-stimulating factor-1 (CSF-1) accelerates rat 
molar eruption, but not incisor eruption (Cielinski et al., 1995; Wise et al., 2005). 
Dexamethasone accelerates incisor eruption, but not molar eruption (Wise et al., 2001). 
In recent years, considerable progress has been made in understanding the biology 
of tooth eruption. Studies have shown that interactions among osteoblasts, osteoclasts, 
and dental follicle involve a complex interplay of regulatory genes that encode various 
transcription factors, proto-oncogenes, and growth factors. For the clinician faced with 
treating both simple and complex dental complications that arise from abnormal tooth 
eruption, as seen in numerous genetic and acquired disorders, knowledge about the basic 
molecular mechanisms involved is essential.  
 
3.3.6 Runx2 and Cleidocranial Dysplasia (CCD) 
Humans with mutations in RUNX2 present with cleidocranial dysplasia (CCD), 
an autosomal dominant disorder defined by several skeletal and dental defects. The 
Runx2 gene is located on the short arm of chromosome 6 in human. Linkage studies and 
mutational analyses have identified loss-of-function mutations in one allele of Runx2 as 
responsible for the defects seen in human CCD (Mundlos et al., 1997). Other individuals 
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affected with CCD are heterozygous for the deletion, frameshift mutation, nonsense 
mutation, missense mutation, splicing mutation and substitution mutation in the coding 
region of Runx2 (Yoshida et al., 2003). Thus, the lack of expression of one allele of 
Runx2 is the basis for the CCD in humans and mice.  
Heterozygous mutations in Runx2 in mice are associated with skeletal defects, 
supernumerary teeth, and delayed eruption (Aberg et al., 2004a). Other dental defects 
include: irregular and compressed permanent tooth crowns, hypoplastic and 
hypomineralization defects in enamel and dentin, an excess of epithelial root remnants, 
the absence of cellular cementum, and abnormally shaped roots(Jensen and Kreiborg, 
1993). This phenotypic change is not evident in every adult Runx2+/- mouse studied and 
suggests an effect of incomplete penetrance.  
Runx2 controls the maturation of both osteoblasts and odontoblasts. Therefore, a 
delay in tooth maturation is expected in RUNX2-deficient tissues. This is reflected in the 
clinical situation, where the dental maturation of CCD subjects is retarded when 
compared with unaffected subjects (Jensen and Kreiborg, 1993).  
3.4 Runx2 and mitogen-activated protein kinase (MAPK) 
The mitogen-activated protein kinase (MAPK) pathway plays an important role in 
osteoblast growth and differentiation by regulation of the transcription factor, Runx2 
(Xiao et al., 2000). ERK/MAPK pathway can also regulate the activity of several other 
tissue/lineage-specific transcription factors, such as MyoD (muscle; (Zetser et al., 2001)), 
Sox9 (cartilage; (Murakami et al., 2000)), as well as PPAR  (adipose tissue; (Adams et 
al., 1997a)). In bone, the ERK/MAPK pathway is a major pathway for signaling 
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transduction from the extracellular environment to the nucleus, and has been implicated 
in the response to a variety of signals, including hormone/growth factor stimulation (Xiao 
et al., 2002c; Jiang et al., 2004), extracellular matrix–integrin binding (Xiao et al., 1997; 
Xiao et al., 2002a), mechanical loading and ECM stiffness (You et al., 2001; Engler et 
al., 2006). 
Osteoblast differentiation requires a type I collagen-containing extracellular 
matrix (ECM), which is  secreted by osteoblast precursors, to form mineralized tissue. 
Production of ECM is followed by induction of osteoblast-related genes, such as OCN, 
BSP, alkaline phosphatase (ALK), parathyroid hormone (PTH)/parathyroid hormone-
related protein receptor, and ultimately, matrix mineralization (Franceschi and Iyer, 1992; 
Franceschi et al., 1994; Franceschi, 1999; Xiao et al., 2002c). Differentiation is controlled 
partially by binding of type I collagen to  integrins that transduce a signal to the 
nucleus via the ERK/MAPK pathway to phosphorylate and activate RUNX2. Blocking 
antibodies or peptides that disrupt the integrin signaling pathway can block ECM-
dependent osteoblast differentiation completely (Xiao et al., 1998a).  
Induction of MC3T3-E1 preosteoblast cell differentiation by growth in ascorbic 
acid, results the secretion of a collagenous ECM.  Over time, this ECM production 
dramatically increases both OCN and BSP gene expression. This matrix response 
requires Runx2 and its DNA binding site in the OCN promoter, osteoblast-specific 
element 2 (OSE2) (Xiao et al., 1997). Interestingly, this Runx2-dependent increase in 
transcriptional activity is not accompanied by a significant change in Runx2 mRNA or 
protein levels although in vitro remarked increases are seen in binding of Runx2 to OSE2 
DNA as measured by gel retardation assays (Xiao et al., 1998a). U0126, a specific 
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ERK1/2 phosphorylation inhibitor, rapidly and specifically inhibits both ERK 
phosphorylation and ECM-dependent induction of the OCN gene expression. Similarly, 
the ability of BMP to stimulate OCN and BSP mRNAs or OCN promoter activity was 
synergistically increased in osteoblasts, and these responses also require matrix signals 
and can be blocked by U0126 (Xiao et al., 2002a). 
Overexpression of a constitutively active MEK (MEK(SP)) increases both 
endogenous OCN mRNA and promoter activity levels, and these responses require 
Runx2 and an intact OSE2 sequence. Runx2 phosphorylation increased after transfection 
of cells with MEK(SP), the kinase immediately before ERK1/2 in the MAPK pathway 
(Xiao et al., 2000). This demonstrates that a MAPK-dependent phosphorylation cascade 
regulates Runx2 activity.  
A transgenic approach was applied to investigate the role of the MAPK pathway 
in bone. Transgenic mice were generated using a 647-bp mouse osteocalcin (Ocn) gene 2 
(mOG2) promoter to drive osteoblast-specific expression of constitutively active (MEK-
SP) or dominant-negative (MEK-DN) forms of the MAPK intermediate MEK. MAPK 
stimulation induced by selective expression of MEK(SP) in osteoblasts accelerated in 
vitro differentiation of calvarial cells, as well as in vivo bone development; whereas 
MEK(DN) was inhibitory. Transgenic mice over-expressing MEK(SP) or MEK(DN) 
were studied in greater detail: (a) Runx2 phosphorylation and transcriptional activity were 
increased in calvarial osteoblasts from mice over-expressing MEK(SP) and decreased in 
cells from MEK(DN) over-expressing mice, and (b) the CCD phenotype (hypomorphic 
clavicles and undemineralized calvaria) of Runx2+/- mice was partially rescued by 
crossing these animals with mice over-expressing MEK(SP); in contrast, when 
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MEK(DN) animals were crossed with Runx2+/– mice, a more severe skeletal phenotype 
were seen. This work demonstrates that the ERK/MAPK pathway has an important in 
vivo function in bone that involves stimulation of RUNX2 phosphorylation and 
transcriptional activity (Ge et al., 2007a), and provides a clinically relevant in vitro and in 
vivo model for the analysis of potential therapeutic modalities involving manipulation of 
MAPK signaling for the treatment of CCD and other bone or dental diseases. 
Runx2 is expressed exclusively in mineralized tissues and their precursors. 
However, in many cases there is a poor correlation between actual Runx2 mRNA or 
protein levels and the expression of osteoblast-related genes. During development, Runx2 
expression precedes osteoblast differentiation and OCN expression by several days (Ducy 
et al., 1997). Also, in several osteoblast cell culture systems, Runx2 protein levels are not 
well correlated with expression of its target genes. For example, cultures of primary 
osteoblasts or MC3T3-E1 preosteoblast cells do not exhibit major changes in Runx2 
protein during in vitro differentiation even though expression of osteoblast marker genes 
like OCN, BSP and ALK is dramatically increased (Xiao et al., 1998a). In addition, 
although both TGF-  and BMP2 dramatically increase Runx2 expression in C2C12 
myoblasts, only BMP treatment can induce osteoblast-specific gene expression (Lee et 
al., 2000). Therefore, these studies indicate that Runx2-dependent transcription is not 
simply regulated by the level of Runx2 protein. These studies imply that Runx2 is 
regulated either by post-translational modification, especially phosphorylation, or by 
protein-protein interactions. 
The Franceschi group further showed that the specific amino acid residues in 
Runx2 necessary for MAPK responsiveness and phosphorylation are located in a 270 
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amino acid proline/serine/threonine-rich region (P/S/T domain) in the C-terminal portion 
of the Runx2 molecule(Xiao et al., 2000; Franceschi et al., 2003). 
3.5 Runx2 and fibroblast growth factor-2 (FGF2) 
 Fibroblast growth factor-2 (FGF2) also stimulates Runx2 phosphorylation through 
the MAPK pathway (Xiao et al., 2002c). FGF2 is an important in vivo regulator of 
skeletal development and growth. Intermittent administration of FGF2 can restore bone 
mass in the overiectomized rat, a well-established model for postmenopausal bone loss 
(Liang et al., 1999). Overexpression of FGF2 in transgenic mice causes premature 
mineralization, achondroplasia and shortening of long bones, whereas disruption of the 
FGF2 gene leads to decreased bone mass and bone formation (Coffin et al., 1995; 
Montero et al., 2000). Furthermore, activating mutations in FGF receptors are associated 
with a series of craniosynostosis syndromes characterized by accelerated 
intramembranous bone formation in calvarial sutures. Interestingly, activating mutations 
in FGFR1 increase Runx2 gene expression and enhance differentiation of calvarial 
osteoblasts (Zhou et al., 2000). FGF2 can also stimulate OCN gene expression in 
MC3T3-E1 preosteoblast cells (Boudreaux and Towler, 1996). 
A major pathway for FGF receptor signaling involves activation of the 
MEK/ERK branch of the MAPK pathway. A series of studies were carried out to 
determine whether FGF2 induction of the OCN gene required MAPK activity and Runx2 
phosphorylation (Xiao et al., 2002c). Initial studies demonstrated that FGF2 rapidly 
induced ERK phosphorylation and stimulated OCN mRNA expression in MC3T3-E1 
cells and in bone marrow stromal cells. FGF2 also stimulated the activity of a 1.3 kb 
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OCN promoter-luciferase reporter gene, whereas this stimulation could be blocked by the 
MEK/ERK inhibitor, U0126. This stimulation was only seen in cells containing wild type 
Runx2 and also required an intact Runx2 binding site in the OCN promoter. A P/S/T 
domain deletion Runx2 mutant did not respond to FGF2.  Furthermore, metabolic 
labeling with [32P]-orthophosphate showed that the Runx2 phosphorylation level was 
increased with FGF2 treatment and that this response could also be blocked by U0126. 
 Taken together, since Runx2 is involved in bone development, tooth 
development, as well as tooth movement (Baumert et al., 2004; Chung et al., 2004; 
Kawarizadeh et al., 2005; Wise and King, 2008), it is important to understand the 



















The Mitogen-activated protein kinase (MAPK) pathway plays an important role in 
osteoblast growth and differentiation. Short-term inhibition of MAPK activity in cell 
culture using specific inhibitors or MEK(DN), a dominant negative form of MEK, 
inhibited osteoblast-specific gene expression and responsiveness to BMPs. Activation of 
the MAPK pathway with MEK(SP), a constitutively active form of MEK, stimulated 
phosphorylation and transcriptional activity of Runx2. To identify and characterize 
MAPK-activating domain(s) in Runx2, Runx2 deletion mutants were made and tested for 
ability to be activated by MAPK in COS-7 cells by transfection. In vitro phosphorylation 
of Runx2 was also examined. The results show deletion of Runx2 from aa528 to aa330 
gradually reduced MAPK-stimulated activity. Runx2 (1-330), which contains the first N-
terminal 330 amino acid residues, could still be dramatically activated by MAPK.   
Further deletion from aa330 to aa258 completely abolished MAPK activation indicating 
that a critical MAPK activating domain is located in this region. Searching the Runx2 
protein sequences in this 72-aa region identified four consensus MAPK phosphorylation 
sites (SP or TP) located at 282(S), 301(S), 319(S), and 326(T), respectively. To determine 
if these sites can be directly phosphorylated by MAPK, five peptides (Table 1 & Fig. 
10A) covering the entire aa330-258 region were synthesized and tested for ability to be 
directly phosphorylated by purified activated ERK1 in vitro in the presence of -32P-ATP. 
ERK1 strongly phosphorylated peptides 2, 3, and 4, each of which contains at least one 
consensus MAPK phosphorylation site, but not peptide 1, which does not contain a 
consensus site. ERK1 was unable to phosphorylate the same peptides (2, 3, and 4) 
containing a mutation (from S to A) in the MAPK phosphorylation site. Functional 
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analysis established the involvement of these three sites in MAPK activation of Runx2. 
Conclusion: Sites 282(S), 301(S), 319(S) of the Runx2 molecule are required for MAPK 




Runx2, a transcription factor related to the Drosophila transcription factor, runt, 
directly stimulates transcription of osteocalcin and other osteoblast-related genes in 
osteoblasts, tooth germs (cells such as odontoblasts, ameloblasts, cementoblasts), and 
some stages of cartilage via binding to OSE2 core sequences (PuCCPuCA/T). Runx2 is 
essential for differentiation of mesenchymal cells into osteoblasts and for mineralization 
in vivo. Heterozygous Runx2 deletions or mutations result in Cleidocranial Dysplasia 
(defects in skeletal and tooth development, hypoplastic clavicles, enlarged fontanelles). 
Runx2 is a major regulator of osteoblast-specific gene expression, and is subject to post-
transcriptional controls including selective proteolysis and phosphorylation. The 
Mitogen-activated protein kinase (MAPK) pathway plays an important role in osteoblast 
growth and differentiation. Short-term inhibition of MAPK activity in cell culture using 
specific inhibitors or MEK(DN), a dominant negative form of MEK, inhibited osteoblast-
specific gene expression and responsiveness to BMPs. Activation of the MAPK pathway 
with MEK(SP), a constitutively active form of MEK, stimulated phosphorylation and 
transcriptional activity of Runx2. Thus, Runx2 is phosphorylated and activated by the 
ERK/MAPK pathway (Xiao, Jiang et al. 2000, 2002). FGF2 bind to FGFRs to induce 
receptor dimerization and subsequent transphosphorylation, which initiates intracellular 
signaling cascades, including activation of MAPK and PKC pathways. A major route for 
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FGF signaling is through the MAPK pathway. This pathway is important for activation 
and phosphorylation of Runx2. 
ERK/MAPK signaling is also important for in vivo bone development. Transgenic 
over-expression of constitutively active or dominant-negative MEK1 in mouse 
osteoblasts, respectively, stimulates or inhibits Runx2 phosphorylation and skeletal 
maturation. Furthermore, the cleidocranial dysplasia phenotype of Runx2 heterozygous 
null mice can be partially rescued by crossing these animals with mice expressing 
constitutively-active MEK1, consistent with the in vivo actions of the ERK/MAPK 
pathway being at least in part mediated by Runx2 (Ge, Xiao,2007).  
To further understand how the ERK/MAPK pathway regulates Runx2 
transcriptional activity, in the present study we identify amino acid residues in Runx2 that 
are phosphorylated in a ERK/MAPK-dependent manner and show that these sites are 




3. MATERIALS AND METHODS 
A. Reagents 
The reagents used in the experiments were obtained from the following sources: 
Tissue culture media Minimum Essential Medium (Alpha-MEM), Dulbecco’s Modified 
Eagle Medium (DMEM), fetal bovine serum, LipofectAMINE from Invitrogen (Grand 
Island, NY); U0126 from Promega (Madison, WI); Mouse anti-Runx2 antibody from 
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), and MBL International Corporation 
(Woburn, MA). Horseradish peroxidese-conjugated goat anti-rabbit IgG from Invitrogen, 
and FGF2 from Upstate Biotechnology (Lake Placid, NY). -[32P]-ATP was purchased 
from Amersham Bioscience (Arlington Heights, IL). Runx2 peptides were synthesized by 
the core facility of the University of Michigan. [35S]-methionine/cysteine translabel from 
Amersham Bioscience (Arlington Heights, IL). 
All other chemicals were analytical grade. 
 
B. Cell Culture 
COS7 cells were cultured in DMEM, 10% FBS, 1% penicillin/Streptomycin. 
Cells were cultured in a humidified CO2 incubator at 37oC. Cell culture medium was 
changed every other day. When cells were confluent, they were detached from 75 cm2 
flasks with Trypsin (Invitrogen), centrifuged, and passed at a proportion of 1:10.  
 
C.  DNA constructions and plasmid expression vectors 
To generate a luciferase reporter plasmid, multimers (six copies) of OSE2 
(Osteoblast-specific cis-acting element) oligonucleotide were cloned into p4luc 
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promoterless luciferase expression vector (6OSE2-Luc) described previously (Ducy and 
Karsenty, 1995; Frendo et al., 1998; Xiao et al., 2002c). pCMVRunx2 expression 
plasmids (wild type, and C-terminal deletions aa1-410, aa1-330, aa1-286, and aa1-258) 
containing cDNAs encoding either wild type Runx2 or deletions under CMV promoter 
control were constructed by ligating the full-length or deletion Runx2 cDNAs into 
pCMC5 described previously (Xiao et al., 2005). Serine mutants of Runx2 or Runx2 
deletions were generated using a Quick Change Site Directed Mutagenesis Kit 
(Stratagene, La Jolla, CA). All sequences were verified by automatic DNA sequencing. 
pCMV5MEK(SP) expression plasmid encoding a constitutively-active mutant of 
MAPK/extracellular signal-regulated kinase (MEK1) was previously described (Zheng 
and Guan, 1993; Ducy and Karsenty, 1995; Xiao et al., 2000). The pCMV5b-gal 
expression plasmid, used as a negative control for Runx2 overexpression experiments, 
was constructed by ligating a full-length bacterial -galactosidase cDNA from plasmid 
pRSVb-gal into the HindIII/BamHI sites of the pCMV5 vector.  
 
D. Transfections 
COS7 cells were plated at a density of 2.5 x 105 cells/cm2 on 35-mm dishes. After 
24 hours, cells were transfected using LipofectAMINE (Invitrogen) according to the 
manufacturer’s instructions. Each transfection contained 0.5µg of the indicated plasmid 
and 0.05 µg of pRL-SV40 containing a cDNA for Renilla reformis luciferase as an 
internal control for transfection efficiency. Cells were then cultured in growth medium 
for 24 hours and then switched to medium containing 0.1% FBS to minimize the impact 
of serum growth factors on MAPK signaling. After an additional 24 hours, cells were 
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harvested and assayed using a Dual Luciferase Assay Kit (Promega, Madison, WI) on a 
Monolight 2010 luminometer (BD Biosciences Pharmingen, San Diego, CA). Firefly 
luciferase activity was normalized to Renilla luciferase activity. For FGF2 experiments, 
after transfection, cells were cultured in growth medium for 24 hours and then switched 
to medium containing 0.1% FBS in the absence or presence of FGF2 at concentration of 
25 ng/ml for another 12 hours, then harvested and assayed by the same procedure 
described above. 
 
E. Western Blot Analysis 
Whole cell extracts were prepared by rinsing cells layers in phosphate-buffered 
saline containing 100 ul of Sigma protease inhibitor cocktail /107 cells. Inhibitor cocktail 
contained 4-(2-amino-ethyl)-benzenesulfonyl fluoride, pepstatin A, trans-
epoxysuccinnyl-L-leu-cylamido (4-guanidino) butane, bestatin, leupeptin, and aprotinin 
and 1.0 mM phenylmethylsulfonyfluoride. Cells were then harvested in 1 X SDS –
polyacrylamide gel electrophoresis loading buffer (2% SDS, 2M urea, 10mM 
dithiothreitol, 1.0 mM phenylmethylsulfonyl fluoride, 10% glycerol, 10 mM Tris-HCl, 
0.002% Bromphenol blue). Failure to use a combination of protease inhibitors led to the 
generation of proteolytic fragments of Runx2. Samples were separated on 4-12% SDS-
PAGE gel, and electrophoretically transferred to a nitrocellulose membrane (Schleicher 
& Schuel, Keene, NH). Primary Runx2 antibodies were used at a dilution of 1:1,000. 
Secondary antibody (horseradish peroxidase-conjugated goat anti-rabbit IgG) was used at 
a dilution of 1:10,000. Immunoreactivity was detected using the ECL chemiluminescence 
reagents (GE Healthcare, piscataway, NJ).  
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F. Metabolic Labeling and Immunoprecipitation of Runx2 
COS7 cells were transfected with Runx2 expression plasmids, cultured for 30 h 
and preincubated in phosphate-free DMEM, 0.1% FBS for 12 h. Labeling was conducted 
for 4 h in phosphate free DMEM containing 200 µCi/mL [32P] orthophosphate 
(Phosphorus-32, Amersham Bioscience) or [35S]-methionine/cysteine translabel 
respectively. Nuclear extracts were prepared as previously described (Xiao et al., 1997) 
and precleaned twice with 50 µl of protein A/G agarose beads. Appropriate antibodies 
were added and incubated for 2 h at 4 ºC with gentle rocking. Immune complexes were 
then collected by the addition of 30 L of protein A/G agarose beads and incubation for 1 
h at 4 ºC followed by centrifugation. Precipitates were washed five times with 1 x 
washing buffer (20 mM HEPES, pH7.6, 50 mM KCl, 1 Mm dithiothreitol, 0.25% 
Nonidet P40, 5 mM NaF, 1 mM EGTA, 5 mM MgCl2, 0.25 mM phenylmethylsulfonyl 
fluoride). The immunoprecipitated complexes were suspended in SDS sample buffer and 
analyzed by SDS-PAGE and autoradiography or Western blot analysis using the 
indicated antibodies. 32P incorporation was measured using a Packard A2024 
InstantImager. 
 
G. In vitro peptide phosphorylation 
 
Synthetic peptides were prepared by the University of Michigan Protein Structure 
Facility. Each peptide (1 g) was incubated with 20 Ci -[32P] ATP and 0.5 µl (300 
units) of recombinant activated MAPK (Calbiochem) in a buffer containing 25 mM Tris-
HCl, pH 7.4, 10 mM MgCl2, 1 mM dithiothreitol, 40 M ATP and 0.5 mM EGTA in a 
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final volume of 25 l. Samples were incubated at 25oC for 30 minutes. Reactions were 
terminated by addition of 25 l 2X SDS sample buffer and boiling samples, and analyzed 
by electrophoresis on 15% SDS gels.  
 
H. Statistical Analysis 
All transfection data are reported as mean + SD based on triplicate independent 
cell cultures from a representative experiment. All experiments were repeated at least 
twice, and qualitatively identical results were obtained. Statistical analyses were 
performed using Instat 3.0 software (GraphPad, Inc., San Diego, CA). A one-way 
ANOVA analysis was performed. Student’s t test was used to test for differences between 
two groups of data. Turkey-Kramer multiple comparisons test was also used to assess 
statistical significance between samples. Differences with a P<0.05 were considered as 




A. ERK/MAPK-dependent phosphorylation and activation of Runx2 requires a 
specific region of the C-terminal P/S/T domain. Activation of the ERK/MAPK pathway 
by overexpression of a constitutively active form of MEK1 or by treatment with FGF2 
was previously shown to stimulate Ocn mRNA expression and promoter activity via a 
mechanism requiring Runx2 (Xiao et al., 2000; Xiao et al., 2002b). An initial deletion 
analysis of the Runx2 coding sequence showed that removal of the entire C-terminal 
proline/serine/threonine-rich (P/S/T) domain (amino acid residues 258-528 in the mouse 
sequence) rendered Runx2 completely resistant to MAPK regulation and 
phosphorylation. In contrast, deletion of the N-terminal Q/A-rich region  (amino acids 1-
108) lowered basal transcriptional activity without affecting MAPK-dependent activation 
(Xiao et al., 2000). Similarly, deletion of the P/S/T domain also rendered Runx2 
unresponsive to activation by FGF2 (Xiao et al.). 
 To more precisely define regions of Runx2 necessary for MAPK responsiveness, 
we carried out a more detailed deletion analysis of the P/S/T domain (Fig.  3, 4, 5, and 6). 
Wild type Runx2 or several C-terminal deletions (to residues 410, 330, 286 and 258) 
were transfected into COS7 cells in the presence or absence of constitutively active 
MEK1 (MEK(SP)) and a p6OSE2-luc Runx2 reporter gene. Samples were then assayed 
for luciferase activity (Fig. 3). C-terminal Runx2 deletions gradually reduced MAPK 
activation of Runx2 transcriptional activity from approximately 9-fold with wild type 
Runx2 to approximately 4.4-fold with the amino acid 410 deletion, 3-fold with the amino 
acid 330 deletion, and 2.3-fold with the amino acid 286 deletion. This stimulation 
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gradually decreased with the 410, 330 and 286 deletions and was completely lost after 






Fig. 3. Identification of Regions in Runx2 necessary for ERK/MAPK-dependent 
transcriptional activation and phosphorylation. COS7 cells were transfected with 
wild type Runx2 or the indicated C-terminal deletions in the presence of control 
-gal or MEK(SP) expression vectors and a 6OSE2-luc reporter as described in 
Methods. Firefly luciferase activity was normalized for transfection efficiency 
using renilla reformis luciferase plasmid. For each group, fold-stimulation in 
MEK(SP) samples was determined. *, Ratio (MEK(SP)/Beta-gal) is significantly 
different at P<0.001. 
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Wild type Runx2 or C-terminal deletions (to residues 410, 330, 286 and 258) 
were transfected into COS7 cells and a p6OSE2-luc Runx2 reporter gene, then treated in 
the presence or absence of FGF2, a natural MAPK activator. Similar to the result 
obtained with MEK(SP) stimulation, C-terminal Runx2 deletions gradually reduced 
MAPK activation of Runx2 transcriptional activity from approximately 6.74-fold with 
wild type Runx2 and the amino acid 410 deletion, 3-fold with the amino acid 330 
deletion, and 1.7-fold with the amino acid 286 deletion. This stimulation gradually 
decreased in the 410, 330 and 286 deletions and was completely lost after deletion to 
residue 258 (Fig. 4). 
In addition, wild type Runx2 and increasing amounts of P/S/T domain deletion 
Runx2 were transfected into COS7 cells in the presence or absence of constitutively 
active MEK1 (MEK(SP)) and a p6OSE2-luc Runx2 reporter gene. Samples were then 
assayed for luciferase activity. The P/S/T domain deleted Runx2 inhibited MAPK 
activation of wild type Runx2 in a dominant negative manner (Fig. 5). 
Furthermore, wild type Runx2 and P/S/T domain deletion Runx2 transfected 
COS7 cells in the presence or absence of constitutively active MEK1 (MEK(SP)) were 
metabolically labeled with [32P]-orthophosphate or [35S]-methionine/cysteine translabel 
and assayed for Runx2 phosphorylation by immunoprecipitation and autoradiography 
(Fig. 6).  The results showed 3.5-fold increase of 32P incorporation by MEK(SP) 
stimulation in wild type Runx2, whereas no stimulation by MEK(SP) was seen in P/S/T 
domain deletion Runx2. There was no significant change in total 35S incorporation, which 





Fig. 4.  Localization of an ERK/FGF2 responsive region. COS7 were transfected 
with the indicated C-terminal Runx2 deletion mutants and 6OSE2-luc. After 
transfection, cells were cultured in growth medium for 24 hours and then 
switched to medium containing 0.1% FBS in the absent or presence of FGF2 at a 
concentration of 25 ng/ml for another 12 hours, then harvested and assayed. 
Firefly luciferase activity was normalized for transfection efficiency using renilla 
reformis luciferase plasmid. For each group fold-stimulation in FGF2 treated 






Fig. 5. The P/S/T domain of Runx2 is required for MAPK activation and 
phosphorylation. The P/S/T domain deleted Runx2 inhibits MAPK activation of 






















Fig. 6. The P/S/T domain of Runx2 is reqired for MAPK activation and 
phosphorylation. Cos7 cells were transfected with Runx2 expression plasmids, 
cultured for 30 h and preincubated in phosphate-free DMEM, 0.1% FBS for 12 h. 
Labeling was conducted for 4 h in phosphate free DMEM or sulfate free DMEM 
containing 200 µCi/mL [32P] orthophosphate (Phosphorus-32, Amersham 
Bioscience) or [35S]-methionine/cysteine translabel, respectively. Nuclear extracts 
were prepared. The immunoprecipitated complexes were suspended in SDS 
sample buffer and analyzed by SDS-PAGE and autoradiography or Western blot 
analysis using indicated antibodies. 32P incorporation was measured using a 
Packard A2024 InstantImager. 
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 Taken together, these results indicate that the minimal region for MAPK 
phosphorylation and activation of Runx2 is between amino acids 258 and 330. 
Subsequent analysis was restricted to this region although it is possible that more C-
terminal sites may also participate in this regulation. 
 
 B. Identification and evaluation of Runx2 phosphorylation sites.  Inspection of the 
peptide sequence of the 72 amino acid region in the Runx2 molecule between 258 to 330 
region (Fig. 10A) identified three putative proline-directed serine phosphorylation sites at 
residues 282, 301 and 319. A similar proline-directed threonine site was also seen (T326). 
To further characterize these consensus MAPK phosphorylation sites, Runx2 mutants 
were generated by introducing single point mutations with substitution of Serine to 
Alanine at S282, 301, or 319 sites (S282A, S301A, S319A), and double-point mutation at 
S301 and 319 sites (S301/319A), and triple-point mutation at all three of these sites 
(S282/301/319A) into full-length of Runx2. Wild type Runx2 or Runx2 point mutation 
expression plasmids were transfected into COS7 cells in the presence or absence of 
(MEK(SP)) and a p6OSE2-luc Runx2 reporter gene. Samples were then assayed for 
luciferase activity. As shown in Fig. 7, the ability of MEK(SP) to stimulate 
transcriptional activity of single point mutation in individual S282A, or S301A, or S319 
mutants  was not significantly changed compared with wild type Runx2. However, the 
ability of MEK(SP) to stimulate transcriptional activity in double-point mutation 
(S310/319A) decreased dramatically,  and was completely lost in  triple-point mutation 






Fig. 7. Mutational analysis of Runx2. COS7 cells were transfected with wild type 
Runx2 or the indicated point mutations or deletions in the presence of control 
Beta-gal or MEK(SP) expression vectors and a 6OSE2-luc reporter as described 
in Methods. Firefly luciferase activity was normalized for transfection efficiency 
using renilla reformis luciferase plasmid. For each group fold-stimulation in 
MEK(SP) samples was determined. *, Ratio (MEK(SP)/Beta-gal) is significantly 
different at P<0.001. 
 
 46 
We also assessed the functionality of the above Runx2 phosphorylation sites in 
mediating the response to FGF2. S/A mutation was generated at all three consensus 
MAPK phosphorylation sites. Wild type or mutated expression plasmids of Runx2 were 
transfected into COS7 cells with 6OSE2+FGF2. As shown in Fig. 8A & 8C, the ability of 
FGF2 to stimulate transcriptional activity in the S/A mutant was partially decreased. 
Runx2 protein levels tested by Western blot were not significantly changed (Fig. 8B). 
This indicates that other pathways maybe involved. Transfection of wild type or S/A 
mutation of Runx2 1-330 and 6OSE2-luc + MEK(SP) plasmids into COS7 cells was used 
to show that the ability of MEK(SP) to stimulate transcriptional activity was completely 
lost in  triple-point mutation (S282/310/319A) Runx2 1-330 (Fig. 9). These results 
indicate that all three consensus MAPK phosphorylation sites are functionally responsible 
for MAPK activation.  
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Fig. 8. Mutational analysis of full-length Runx2. A. Wild type or mutated 
expression plasmids of full-length Runx2 were transfected into COS7 cells with 
6OSE2-luc. After transfection, cells were cultured in growth medium for 24 hours 
and then switched to medium containing 0.1% FBS in the absent or presence of 
FGF2 at a concentration of 25 ng/ml for another 12 hours, then harvested and 
assayed. B. Runx2 protein levels tested by Western blot. C. Fold stimulation of 








Fig. 9. Mutational analysis of Runx3 1-330 deletion. Mutations of three consensus 
MAPK phosphorylation sites (282, 301, 319) from Ser to Ala of Runx2 1-330 
deletion transfected with 6OSE2-luc in COS7 cells reduced MEK(SP) stimulation 
of Runx2 1-330 deletion. For each group fold-stimulation in MEK(SP) samples 
was determined. *, Ratio (MEK(SP)/Beta-gal) is significantly different at 
P<0.001. 
 
To determine whether MAPK can directly phosphorylate Runx2 peptides in vitro, 
eight synthesized Runx2 peptides (see Table 1 & Fig. 10A), which contain one consensus 
MAPK phosphorylation site or the same peptide containing a mutation at the MAPK 
phosphorylation site or none of those sites were examined by in vitro phosphorylation 
experiments. Incubation of peptides spanning the 260 to 333 region with active Erk1 and 
-32P-ATP revealed that S282, 301 and 319 were all phosphorylated in vitro while S/A 
substitution at each site prevented phosphorylation (Fig 10B). In contrast, T326 was not 
phosphorylated under these conditions (i.e. Introduction of an S319A mutation in the 
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316-333 peptide blocked phosphorylation).  Peptides containing residues 260-279 and 
511-528 were also not phosphorylated. This result indicated that MAPK can directly 
phosphorylate Runx2 peptides in vitro. 
 
Table 1. Peptide sequence 
 
aa260-279 (peptide 1) PHPSMRVGVPPQNPRPSLNS 
aa277-296 (peptide 2) LNSAPSPFNPQGQSQITDPR 
aa277-296 (S282A) LNSAPAPFNPQGQSQITDPR 
aa297-316 (peptide 3) QAQSSPPWSYDQSYPSYLSQ 
aa297-316 (S301A) QAQSAPPWSYDQSYPSYLSQ 
aa316-333 (peptide 4) QMTSPSIHSTTPLSSTRG 
aa316-333 (S319A) QMTAPSIHSTTPLSSTRG 
aa511-528 (peptide 5) PTVLNSSGRMDESVWRPY 
 
 
Taken together, studies with full-length Runx2, Runx2 1-330 and in vitro 
phosphorylation indicate that S282, 301 and S319 phosphorylation sites are critical for 
MAPK responsiveness although more distal sites outside the 1-330 region may also be 























 Fig. 10. MAPK directly phosphorylates synthesized Runx2 peptides in vitro. 
Runx2 peptides were incubated with activated ERK1 and -[32P] ATP. ERK1 
strongly phosphorylated the peptide, which contains at least one consensus 
MAPK phosphorylation site, but not the ones without a consensus site. ERK1 was 
















































































In this study, we identified and characterized the MAPK phosphorylation sites in 
the Runx2 molecule that are necessary for transcriptional activity. Our studies show that:  
1) The P/S/T domain of Runx2 is required for MAPK-dependent phosphorylation; 2) The 
amino acid 258 to 330 region in Runx2 molecule is necessary for MAPK 
responsiveness/phosphorylation. 3) Three MAPK phosphorylation sites, S282, S301, 
S319, in Runx2 are required for MAPK-dependent activation of Runx2 transcriptional 
activity and osteoblast differentiation. These sites are directly phosphorylated by 
activated ERK1 in vitro and functionally responsible for MAPK activation. Recent results 
of our group also show that these three sites can be phosphorylated in intact cells. 
Furthermore, inactivating S to A mutations greatly reduced the ability of Runx2 to 
stimulate expression of Ocn and Bsp mRNAs in Runx2-/- calvarial cells and blocked 
Runx2-dependent induction of osteoblast gene expression and differentiation in a 
mesenchymal cell line. In other experiments not show here, S to E (glutamic acid) 
mutations, which mimic the charge density of phosphorylated amino acids, activated 
Runx2-dependent transcription (Ge et al. in preparation). Taken together, these studies 
demonstrate that MAPK-dependent phosphorylation plays an important role in 
controlling Runx2 transcriptional activity in bone.  
 Runx2 proteins are subject to post-translational modifications that affect their 
activity (see reviews  by Franceschi and Xiao, 2003; Bae and Lee, 2006; Franceschi et 
al., 2007). As one of the major signal transduction pathways in bone, the ERK/MAPK 
pathway is able to integrate stimuli from growth and differentiation factor binding to 
receptor tyrosine kinases (Cobb et al., 1991), ECM-integrin binding and focal adhesion 
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kinase activation (FAK) (Franceschi and Xiao, 2003), certain non-genomic actions of 
estrogens (Kousteni et al., 2003) and mechanical stimulation mediated by FAK activation 
(Moalli et al., 2001) and connexin 43 up-regulation (Lecanda et al., 2000). It also has 
important functions in the differentiation of post-mitotic mesenchymal and neuronal cells 
(Kao et al., 2001; Yao et al., 2003) and regulates the activity of several tissue-specific 
transcription factors including MyoD (muscle(Zetser et al., 2001)), Sox9 
(cartilage(Murakami et al., 2000)) and PPAR  (adipose(Adams et al., 1997b)). 
Furthermore, as previously shown by this laboratory, in vivo transgenic stimulation of 
ERK/MAPK signaling in osteoblasts accelerates bone development and is able to 
partially rescue the cleidocranial dysplasia phenotype of Runx2 haploinsufficient 
mice(Ge et al., 2007b).  Based on this work, it is likely that the phosphorylation sites we 
identified are critical for regulating Runx2 activity in vivo and may function to integrate 
the osteogenic response to hormonal, mechanical and environmental stimuli. 
 Although the three phosphorylation sites identified in this study are clearly 
important for Runx2 transcriptional activity, it is possible that other sites also participate 
in the response to ERK/MAPK stimulation. Our deletion/mutation analysis showed that 
the C-terminal 330 amino acid residues of Runx2 retained the ability to be activated by 
MAPK and that this activity could be explained by phosphorylation at S282, S301 and 
S319. Furthermore, combined S/A mutations in the context of full-length Runx2 greatly 
attenuated the ability of Runx2 to induce expression of Ocn, Bsp and alkaline 
phosphatase. However, there are a total of 13 proline-directed serine consensus 
phosphorylation sites in the Runx2 sequence, some of which may also participate in the 
MAPK response. In fact, deletion analysis showed a gradual loss of MAPK-dependent 
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activation of Runx2 with progressively larger C-terminal deletions. It is, therefore, 
possible that phosphorylation sites in the region between residues 330 and 528 may also 
participate in the MAPK response, possibly functioning as secondary sites after priming 
phosphorylations occur at S282, S301 and 319.  In addition, S282 /301/319A mutations 
only partially blocked activation of the 6OSE2-luc reporter by FGF2 (Fig.8A). In this 
regard, a recent study by Kim and coworkers reported that FGF2 also activates Runx2 via 
phosphorylation by PKC  at S247 (Kim et al., 2006). Thus, it is possible that FGF2 
activates Runx2 transcriptional activity by phosphorylating both ERK/MAPK and PKC 
sites.  
 Runx family members exhibit a high degree of amino acid sequence homology, 
particularly in the DNA binding or Runt domain. Although the C-terminal P/S/T domain 
of Runx proteins is not highly conserved, the three phosphorylation sites we identified in 
Runx2 are also present in Runx1 (but not in Runx3). Interestingly, EGF-dependent 
activation of the ERK/MAPK pathway can stimulate Runx1 transcriptional activity via 
phosphorylation on these sites (Tanaka et al., 1996). Similarly, stimulation of Runx1 by 
phorbol esters, which is also largely dependent on ERK/MAPK, requires these same two 
sites together with an additional conserved site equivalent to T326 in Runx2 (Zhang et 
al., 2004). Runx1 is essential for hematopoietic cell differentiation (Tanaka et al., 1995; 
Tanaka et al., 1996) and is also a frequent site for chromosomal translocations in acute 
myelogenous leukemia. Consistent with this oncogenic activity, transfection of Runx1 
into fibroblasts stimulates anchorage-independent growth and transformation. 
Interestingly, S/A mutations at S249 and S266 in Runx1 (equivalent to S301,319 in 
Runx2) were shown to inhibit the growth of NIH 3T3 fibroblasts in soft agar, a common 
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assay for cell transformation (Tanaka et al., 1996). Runx2 can also function as an 
oncogene under certain conditions and has been associated with cell proliferation and 
migration of breast cancer cells (Barnes et al., 2004; Pratap et al., 2006). It is, therefore, 
possible that ERK/MAPK dependent phosphorylation of Runx2 at S301, 319 could also 
be associated with this metastasis-related behavior. 
 It is not presently understood how phosphorylation of Runx2 stimulates 
transcription. Runx2 is also known to serve as a docking site for many other nuclear 
factors that can form active or inactive transcription complexes on chromatin (Lian et al., 
2004). These complexes subsequently recruit additional factors including histone 
acetyltransferases like p300/CBP to modify chromatin structure thereby allowing the 
initiation of transcription. Interestingly, the ERK/MAPK-dependent phosphorylation of 
Runx1 discussed above is associated with the dissociation of the histone deacetylase co-
factor, mSin3a, from Runx1, thereby allowing subsequent increases in histone 
acetylation(Imai et al., 2004). Since Runx1 phosphorylation sites are conserved in Runx2, 
this observation provides a plausible mechanism for how ERK/MAPK phosphorylation 
could alter Runx2-dependent transcription. 
 In addition to the ERK/MAPK-dependent regulation of Runx2 described herein, 
several other types of post-translational modifications have been described for this 
molecule. PTH/PKA-mediated phosphorylation of a C-terminal Runx2 site was 
correlated with induction of MMP13 (Selvamurugan et al., 2000). More recently, Cdk4-
mediated phosphorylation at S472 was shown to target Runx2 for ubiquitination and 
proteosomal degradation during the cell cycle (Shen et al., 2006) while cdc2 
phosphorylation at S451 was shown to be necessary for cell cycle progression of 
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endothelial cells(Qiao et al., 2006). Also, GSK3 -dependent phosphorylation of Runx2 at 
S369-S373-S377 was shown to reduce transcriptional activity (Kugimiya et al., 2007). 
Most recently, three phosphorylation sites (S28, S347 and T340) of Runx2 were shown to 
be critical for PTH activity via protein kinase A (PKA), which phosphorylates and 
stimulates Runx2-dependent activation of the MMP-13 promoter (Selvamurugan et al., 
2009). Lastly, Runx2 can be acetylated on critical lysine residues by p300 
acetyltransferase. This modification, which is stimulated by BMP2, increases 
transcription and stabilizes Runx2 against proteosomal degradation (Jeon et al., 2006). 
Thus, posttranslational modification appears to be a common mechanism for regulating 
Runx2 activity and stability. 
 In summary, phosphorylation of Runx2 at S282, S301 and S319 clearly has an 
important regulatory role in Runx2-dependent transcription since mutation of these sites 
in the context of the intact Runx2 molecule severely attenuated the ability of Runx2 to 
stimulate osteoblast-specific gene expression during differentiation. Ongoing in vivo 
studies will be necessary to assess the full impact of Runx2 phosphorylation to the overall 
activity of this molecule during skeletal development and remodeling.  
 Recent studies from our group also show that fluid flow shear stress, a kind of 
mechanical loading, induces osteoblast-specific gene expression through a MAPK-
mediated process (Yan Li, personal communication). The results of this study provide the 
foundation for future therapeutic strategies to promote bone formation for implant 
healing, osteointegration, as well as tooth movement in orthodontics.  Based on our 
mutational analysis, future therapeutic means can be developed using knock-in models to 
manipulate the phosphorylation sites in Runx2 to accelerate or delay the bone formation 
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for different therapeutic purposes. Furthermore, our transgenic model of MEK(SP), and 
MEK(DN) also provides the means to cure or rescue CCD patients using Runx2 
mutation/deletion. A chemotherapeutic approach could develop drugs to activate or 
inhibit MEK activity. 
 Runx2 plays an important role in dental development. Runx2 is required for the 
differentiation of odontoblasts and osteoblasts lining bone in the periodontal space 
(D'Souza et al., 1999). The defects seen in the dentition of patients affected with CCD are 
thought to arise from a disruption in the bone remodeling process. In addition to increased 
density in the maxilla and mandible, multiple supernumerary teeth are present that show a 
marked delay or arrest in eruption (Jensen and Kreiborg, 1993). However, the mechanism 
used by Runx2 to control in dental development is poorly understood. It will be of great 




The P/S/T domain of Runx2 is required for MAPK-dependent phosphorylation. 
The region from amino acid 258 to 330 in the Runx2 molecule is necessary for MAPK 
responsiveness/phosphorylation. Three MAPK phosphorylation sites, S282, S301, S319, 
were identified in Runx2 and shown to be directly phosphorylated by MAPK and 
functionally responsible for MAPK activation. 
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